Skip to content

Zymeworks ZYME Quick ratio

Quick ratio at other companies

Pfizer logo
PfizerPFE
1.2×0.0×
Amgen logo
AmgenAMGN
+0.1×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
7.6×-0.7×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
15.1×-4.3×
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
13.9×+3.7×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
+0.6×

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Calculated from Zymeworks’s reported figures.

Based on the most recent quarter.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's quick ratio?
Zymeworks (ZYME) reported quick ratio of 10.8× in Q1 2026.
How has Zymeworks's quick ratio changed year-over-year?
Zymeworks's quick ratio increased by 129.8% year-over-year, from 4.7× to 10.8×.
What is the long-term trend for Zymeworks's quick ratio?
Over 4 years (2021 to 2025), Zymeworks's quick ratio has grown at a 10.0% compound annual growth rate (CAGR), from 4× to 5.9×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.